Form 4: ORAGENICS Director Natasha Giordano Receives Equity Awards

Natasha Giordano, a Director at ORAGENICS INC, was granted 163,320 stock options as part of her non-employee director compensation program.

Summary

• Natasha Giordano, a Director of ORAGENICS INC (OGEN), acquired 163,320 derivative securities in the form of stock options.
• The first award consists of 38,320 options to purchase common stock with an exercise price of $1.03 per share.
• The second award consists of 125,000 options to purchase common stock with an exercise price of $0.93 per share.
• Both sets of options were granted on December 11, 2025, vest immediately, and expire on December 11, 2035.
• These awards are part of the Company's non-employee director compensation program under the 2021 Equity Incentive Plan.
• The 38,320 options represent an initial equity award upon appointment to the Board, with an exercise price based on the closing price immediately prior to appointment.
• The 125,000 options represent a standard award, with an exercise price based on the closing price on the date of grant.

Sentiment

Score: 7

Explanation: The grant of immediately vesting stock options to a non-employee director is a standard practice to align director incentives with shareholder interests, reflecting a positive aspect of corporate governance.

Positives

• The options vest immediately, providing immediate beneficial ownership to the director.
• The equity awards align the director's financial interests with those of the shareholders, promoting long-term value creation.
• The awards are part of a structured non-employee director compensation program, indicating a clear governance framework.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future performance or strategic direction, as it is solely a report of an insider transaction.

Industry Context

The granting of stock options to non-employee directors is a common practice across various industries, particularly in biotechnology and pharmaceutical sectors like ORAGENICS, to attract and retain qualified board members and align their interests with long-term shareholder value.

Comparison to Industry Standards

• The immediate vesting of director options is a common practice, especially for initial awards or annual grants, to ensure directors are compensated for their service and have an immediate stake in the company's performance.
• The use of the 2021 Equity Incentive Plan for these awards is standard for publicly traded companies, providing a framework for equity-based compensation.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for minor dilution upon exercise of options, but also benefits from increased alignment of director's interests with long-term company performance.
• Natasha Giordano (Director): Increased personal stake in the company's success through equity ownership.

Next Steps

• Natasha Giordano may choose to exercise her options at any time between the exercisable date (12/11/2025) and the expiration date (12/11/2035).

Key Dates

Keywords

ORAGENICS INC, OGEN, Form 4, Insider Transaction, Stock Options, Director Compensation, Equity Award, Natasha Giordano, Corporate Governance